Document Detail

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
MedLine Citation:
PMID:  23866179     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome.
BACKGROUND: Greater platelet inhibition has been associated with improved angiographic outcomes before and after percutaneous coronary intervention (PCI). Therefore, it was hypothesized that treatment with ticagrelor, which achieves more rapid, higher, and more consistent platelet inhibition, would be associated with improved angiographic outcomes when compared with those of clopidogrel treatment.
METHODS: The angiographic cohort consists of 2,616 patients drawn from the 18,624-patient PLATO trial. Clopidogrel naïve or pre-treated patients were randomized to 180 mg of ticagrelor or 300 mg of clopidogrel (75 mg for clopidogrel pre-treated patients). PCI patients were administered, as per treatment group: 1) an additional 90 mg of ticagrelor if >24 h following the initial loading dose; or 2) an optional further 300 mg of clopidogrel or placebo (total 600 mg) prior to PCI. The substudy primary endpoint was the incidence of post-PCI TIMI (Thrombolysis In Myocardial Infarction) myocardial perfusion grade 3 (TMPG 3) among patients who received a study drug prior to PCI.
RESULTS: In total, 21.3% of patients were pretreated with clopidogrel prior to randomization. There was a short time interval between randomization and PCI (median: 0.68 [interquartile range (IQR): 0.30 to 2.21] h) among all patients. Post-PCI TMPG 3 was similar between the ticagrelor and clopidogrel groups (47.1% vs. 46.9%; p = 0.96). Likewise, the following pre-PCI outcomes were similar in the ticagrelor and clopidogrel groups, respectively: TMPG 3 (30.5% vs. 31.2%), TIMI flow grade 3 (37.1% vs. 39.3%), corrected TIMI frame count (median: 100 vs. 71 frames), TIMI thrombus grade 0 (24.1% vs. 27.6%), minimum lumen diameter (median: 0.3 [IQR: 0.0 to 0.6] vs. 0.3 [IQR: 0.0 to 0.6] mm) and percentage of diameter stenosis (median: 89 [IQR: 78 to 100] vs. 89 [IQR: 77 to 100]).
CONCLUSIONS: Neither coronary flow nor myocardial perfusion, evaluated on coronary angiograms performed before or following PCI procedures within a few hours after the start of oral antiplatelet treatment in the setting of acute coronary syndromes, demonstrated a difference with ticagrelor versus clopidogrel. (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome [PLATO]; NCT00391872).
Vijay Kunadian; Stefan K James; Daniel M Wojdyla; Cafer Zorkun; Jinhui Wu; Robert F Storey; Ph Gabriel Steg; Hugo Katus; Hakan Emanuelsson; Jay Horrow; Juan Maya; Lars Wallentin; Robert A Harrington; C Michael Gibson
Related Documents :
24210989 - Spanish catheter ablation registry. 12th official report of the spanish society of card...
23151909 - 1,25-dihydroxy vitamin d and coronary microvascular function.
23769489 - Comparison of systolic and diastolic criteria for isolated lv noncompaction in cmr.
24768609 - Epicardial linear electroporation ablation and lesion size.
17913269 - Acute myocardial infarction in a patient with anomalous origin of the right coronary ar...
24022659 - Insulin resistance is a major determinant of myocardial blood flow impairment in angina...
24747279 - One dose of oral hexarelin protects chronic cardiac function after myocardial infarction.
23557229 - Fast diastolic swinging motion of the mitral valve as a clinical marker of familial hyp...
9805119 - Risks associated with removal of ventricular epicardial pacing wires after cardiac surg...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  6     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-07-19     Completed Date:  2014-02-14     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  671-83     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / physiopathology,  radiography,  therapy*
Adenosine / administration & dosage,  analogs & derivatives*,  therapeutic use
Administration, Oral
Coronary Angiography*
Coronary Circulation
Coronary Stenosis / physiopathology,  prevention & control*,  radiography
Coronary Thrombosis / physiopathology,  prevention & control*,  radiography
Coronary Vessels / drug effects*,  physiopathology,  radiography
Double-Blind Method
Logistic Models
Middle Aged
Myocardial Perfusion Imaging
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / administration & dosage,  therapeutic use*
Predictive Value of Tests
Ticlopidine / administration & dosage,  analogs & derivatives*,  therapeutic use
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Ticagrelor; A74586SNO7/clopidogrel; K72T3FS567/Adenosine; OM90ZUW7M1/Ticlopidine
Comment In:
JACC Cardiovasc Interv. 2013 Jul;6(7):684-6   [PMID:  23866180 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery dis...
Next Document:  Prognostic significance of bleeding location and severity among patients with acute coronary syndrom...